Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Arata Azuma

Showing results (181-190 of 221) with videos related to

Pageof 23
Sort By:
American Journal of Respiratory and Critical Care Medicine|May 5, 2026
Pamufetinib (TAS-115) for Chronic Fibrosing Interstitial Lung Diseases with a Progressive Phenotype: A double-blind, multicenter, phase 2b Clinical TrialRyo Okuda, Yasuhiko Nishioka, Yasuhiro Kondoh, et al.
Internal Medicine (Tokyo, Japan)|November 21, 2017
Prognostic Factors in the Acute Exacerbation of Idiopathic Pulmonary Fibrosis: A Retrospective Single-center StudyKenichiro Atsumi, Yoshinobu Saito, Naoyuki Kuse, et al.
BMJ Open Respiratory Research|August 19, 2023
Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with idiopathic pulmonary fibrosis (FIBRONEER-IPF)Luca Richeldi, Arata Azuma, Vincent Cottin, et al.
Respiratory Medicine|September 26, 2021
Efficacy and safety of nintedanib in Japanese patients with progressive fibrosing interstitial lung diseases: Subgroup analysis of the randomised, double-blind, placebo-controlled, phase 3 INBUILD trialYoshikazu Inoue, Takafumi Suda, Hideya Kitamura, et al.
The European Respiratory Journal|December 16, 2014
Safety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosisTakashi Ogura, Hiroyuki Taniguchi, Arata Azuma, et al.
Respiratory Investigation|November 19, 2013
Consensus statement for the diagnosis and treatment of drug-induced lung injuriesKeishi Kubo, Arata Azuma, Minoru Kanazawa, et al.
Respiratory Medicine|January 23, 2019
Lung function outcomes in the INPULSIS<sup>®</sup> trials of nintedanib in idiopathic pulmonary fibrosisKevin K Brown, Kevin R Flaherty, Vincent Cottin, et al.
Biomedicines|October 24, 2020
Nrf2 Lowers the Risk of Lung Injury via Modulating the Airway Innate Immune Response Induced by Diesel Exhaust in MiceYing-Ji Li, Takako Shimizu, Yusuke Shinkai, et al.
Pulmonary Pharmacology & Therapeutics|March 19, 2017
XPLN is modulated by HDAC inhibitors and negatively regulates SPARC expression by targeting mTORC2 in human lung fibroblastsKoichiro Kamio, Arata Azuma, Jiro Usuki, et al.
Biochemical and Biophysical Research Communications|June 27, 2012
α1,6-Fucosyltransferase (Fut8) is implicated in vulnerability to elastase-induced emphysema in mice and a possible non-invasive predictive marker for disease progression and exacerbations in chronic obstructive pulmonary disease (COPD)Koichiro Kamio, Takayuki Yoshida, Congxiao Gao, et al.
Pageof 23

Showing results (181-190 of 221) with videos related to

Sort By:
Pageof 23
American Journal of Respiratory and Critical Care Medicine|May 5, 2026
Pamufetinib (TAS-115) for Chronic Fibrosing Interstitial Lung Diseases with a Progressive Phenotype: A double-blind, multicenter, phase 2b Clinical TrialRyo Okuda, Yasuhiko Nishioka, Yasuhiro Kondoh, et al.
Internal Medicine (Tokyo, Japan)|November 21, 2017
Prognostic Factors in the Acute Exacerbation of Idiopathic Pulmonary Fibrosis: A Retrospective Single-center StudyKenichiro Atsumi, Yoshinobu Saito, Naoyuki Kuse, et al.
BMJ Open Respiratory Research|August 19, 2023
Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with idiopathic pulmonary fibrosis (FIBRONEER-IPF)Luca Richeldi, Arata Azuma, Vincent Cottin, et al.
Respiratory Medicine|September 26, 2021
Efficacy and safety of nintedanib in Japanese patients with progressive fibrosing interstitial lung diseases: Subgroup analysis of the randomised, double-blind, placebo-controlled, phase 3 INBUILD trialYoshikazu Inoue, Takafumi Suda, Hideya Kitamura, et al.
The European Respiratory Journal|December 16, 2014
Safety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosisTakashi Ogura, Hiroyuki Taniguchi, Arata Azuma, et al.
Respiratory Investigation|November 19, 2013
Consensus statement for the diagnosis and treatment of drug-induced lung injuriesKeishi Kubo, Arata Azuma, Minoru Kanazawa, et al.
Respiratory Medicine|January 23, 2019
Lung function outcomes in the INPULSIS<sup>®</sup> trials of nintedanib in idiopathic pulmonary fibrosisKevin K Brown, Kevin R Flaherty, Vincent Cottin, et al.
Biomedicines|October 24, 2020
Nrf2 Lowers the Risk of Lung Injury via Modulating the Airway Innate Immune Response Induced by Diesel Exhaust in MiceYing-Ji Li, Takako Shimizu, Yusuke Shinkai, et al.
Pulmonary Pharmacology & Therapeutics|March 19, 2017
XPLN is modulated by HDAC inhibitors and negatively regulates SPARC expression by targeting mTORC2 in human lung fibroblastsKoichiro Kamio, Arata Azuma, Jiro Usuki, et al.
Biochemical and Biophysical Research Communications|June 27, 2012
α1,6-Fucosyltransferase (Fut8) is implicated in vulnerability to elastase-induced emphysema in mice and a possible non-invasive predictive marker for disease progression and exacerbations in chronic obstructive pulmonary disease (COPD)Koichiro Kamio, Takayuki Yoshida, Congxiao Gao, et al.
Pageof 23